

HR 7324

Preserving Access to Orphan Drugs Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 17, 2018

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jan 2, 2019)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/7324>

Sponsor

Name: Rep. Kelly, Mike [R-PA-3]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Dec 17, 2018
Ways and Means Committee	House	Referred to	Jan 2, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 17, 2018)

Preserving Access to Orphan Drugs Act of 2018

This bill amends the Patient Protection and Affordable Care Act to expand the definition of orphan drug for purposes of the annual fee paid by brand name prescription drug manufacturers and importers to include medications for rare conditions that were, prior to 2011, approved or in clinical trials. (Drug manufacturers and importers pay an annual fee based on their sales of brand name prescription drugs, excluding sales of orphan drugs.)

Actions Timeline

- **Jan 2, 2019:** Referred to the Subcommittee on Health.
- **Dec 17, 2018:** Introduced in House
- **Dec 17, 2018:** Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.